Gold prices remain near record highs; Fed cut bets prompt weekly gains
Director Mark E. Saad of Axsome Therapeutics (NASDAQ:AXSM) sold 9,127 shares of common stock on September 5, 2025. The sales were executed at a weighted average price of $125.07, resulting in a total transaction value of $1,141,513. The prices for the sales ranged from $125.00 to $125.22. According to InvestingPro data, the stock has shown strong momentum with a 47.9% gain year-to-date, though technical indicators suggest the stock may be in overbought territory.
On the same day, Saad also exercised options to acquire 9,127 shares of Axsome Therapeutics common stock at an exercise price of $9.00, for a total value of $82,143. These options were set to expire in the next two months.
Following the sale, Saad directly owns 10,002 shares of Axsome Therapeutics. He also indirectly holds 300 shares.
In other recent news, Axsome Therapeutics has been the focus of several analyst ratings and developments. Wells Fargo initiated coverage on Axsome Therapeutics with an Overweight rating and set a price target of $163.00, as the company plans to submit a supplemental New Drug Application for its AXS-05 treatment for Alzheimer’s Disease Agitation in the third quarter of 2025. Meanwhile, H.C. Wainwright reiterated its Buy rating with a $180.00 price target, following a generic challenge to Axsome’s Symbravo medication. This challenge arose after Apotex Inc. submitted an Abbreviated New Drug Application to the FDA for a generic version of Symbravo.
Mizuho also maintained its Outperform rating and set a price target of $200.00, emphasizing the ongoing generic challenge to Symbravo. Axsome received a Paragraph IV Certification Notice Letter from Apotex, indicating the company’s intent to produce a generic version of Symbravo. RBC Capital reiterated an Outperform rating on Axsome, with a price target of $189.00, citing confidence in the potential approval of AXS-05, supported by the FDA’s demonstrated flexibility with neuro-psychiatric drugs. These developments highlight the ongoing challenges and opportunities facing Axsome Therapeutics in the pharmaceutical market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.